← board
CING
distress 5/10 · elevated risk$4.79-1%today-59% from 52w high
Lead: ADHD
Revenue
pre-revenue
Liquidity
$26M
Runway
1.3 yrs
Shares 1y
+145%
Price & events
-10.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
+8.1%
1W
-0.8%
1M
-14.8%
3M
-1.8%
6M
-14.0%
1Y
+10.3%
2Y
—
5Y
-99.6%
All
Overview
- Market Cap
- $63.59M
- Volume
- 7.94K
- 52 Week Range
- $3.33 – $11.66
- Total Shares
- 13.28M
- Float Shares
- 12.94M
- Short %
- 14.71%
- % Held by Insiders
- 30.54%
- % Held by Institutions
- 8.86%
- RVOL
- 0.03x
- Beta
- -0.92
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 13,276,022 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $23 (+380% upside) · 5 analysts
- 2026-06-08Ascendiant CapitalBuy
- 2026-05-26HC Wainwright & Co.Buy
- 2026-04-08Ascendiant CapitalBuy
- 2026-03-23Roth CapitalBuy
- 2025-12-08Ascendiant CapitalBuy
- 2025-11-19Roth CapitalBuy
Competitors — ADHD
Recent news
- 2026-07-22Cingulate (CING) Registration filing Summary - Quartr
- 2026-07-21Form 4 Cingulate Inc For: 21 July By Investing.com - Investing.com Canada
- 2026-07-14Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information - Minichart
- 2026-07-14Cingulate Inc. Announces Board and Committee Changes, Effective July 9, 2026 - marketscreener.com
- 2026-07-14Cingulate (Nasdaq: CING) adds 625K incentive shares, CEO named chair - Stock Titan
- 2026-07-14Price to earnings forward of Cingulate Inc. – BOATS:CINGW - TradingView
- 2026-07-05Enterprise value to revenue forward of Cingulate Inc. – NASDAQ:CING - TradingView
- 2026-07-02Cingulate added to Russell 3000E Index By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.